Cargando…
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...
Autores principales: | Makker, Vicky, Colombo, Nicoletta, Herráez, Antonio Casado, Monk, Bradley J., Mackay, Helen, Santin, Alessandro D., Miller, David S., Moore, Richard G., Baron-Hay, Sally, Ray-Coquard, Isabelle, Ushijima, Kimio, Yonemori, Kan, Kim, Yong Man, Guerra Alia, Eva M., Sanli, Ulus A., Bird, Steven, Orlowski, Robert, McKenzie, Jodi, Okpara, Chinyere, Barresi, Gianmaria, Lorusso, Domenica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414727/ https://www.ncbi.nlm.nih.gov/pubmed/37058687 http://dx.doi.org/10.1200/JCO.22.02152 |
Ejemplares similares
-
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
por: Yonemori, Kan, et al.
Publicado: (2022) -
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
por: Makker, Vicky, et al.
Publicado: (2023) -
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021) -
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020) -
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE‐826
por: Nishio, Shin, et al.
Publicado: (2022)